The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

NSIP — Nonspecific Interstitial Pneumonia (Cellular and Fibrotic Subtypes)

Idiopathic interstitial pneumonia distinct from IPF, characterized by temporally and spatially uniform interstitial inflammation and fibrosis without UIP architectural distortion; classified into cellular NSIP (predominant inflammation, better prognosis) and fibrotic NSIP (predominant fibrosis, intermediate prognosis between cellular NSIP and IPF); strongly associated with connective tissue disease (especially scleroderma, polymyositis-dermatomyositis, antisynthetase syndrome), drug toxicity, hypersensitivity pneumonitis; treated with immunosuppression for cellular and inflammatory components, antifibrotic agents (nintedanib) for progressive fibrotic NSIP.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Göğüs Hastalıkları department. Book Appointment →

What is NSIP — Nonspecific Interstitial Pneumonia (Cellular and Fibrotic Subtypes)?

Nonspecific Interstitial Pneumonia (NSIP) is one of the major idiopathic interstitial pneumonias (IIPs) classified per ATS/ERS 2013 international multidisciplinary classification, distinct from idiopathic pulmonary fibrosis (IPF) and other IIP subtypes. The term 'nonspecific' refers to histopathologic appearance lacking specific features of other IIPs (UIP, DIP, AIP, COP, RB-ILD, LIP). NSIP is now recognized as a distinct entity with characteristic clinical, radiologic, and histopathologic features.

Histopathology: temporally and spatially uniform interstitial inflammation and fibrosis (in contrast to spatially heterogeneous fibrosis with fibroblastic foci, honeycombing, and architectural distortion of UIP); no significant architectural disruption; preservation of alveolar architecture; uniform involvement throughout the biopsy. Two NSIP subtypes recognized: (1) Cellular NSIP — predominant interstitial chronic inflammation (lymphoplasmacytic infiltrate, often with germinal centers) with little or no fibrosis; better prognosis with 5-year survival >90 percent; often responsive to corticosteroid and immunosuppressive therapy; (2) Fibrotic NSIP — predominant interstitial fibrosis with mild inflammation; intermediate prognosis between cellular NSIP and IPF (5-year survival 70–80 percent); progressive fibrotic course possible.

Etiology and associations: approximately one-third of NSIP cases are idiopathic without identifiable cause; two-thirds are secondary to: (1) Connective tissue disease (CTD) — most common cause, especially systemic sclerosis (scleroderma — NSIP is most common ILD pattern in scleroderma, occurring in 40 percent of cases), mixed connective tissue disease (MCTD), polymyositis-dermatomyositis with antisynthetase syndrome (anti-Jo-1, anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, anti-KS antibodies), Sjögren syndrome, rheumatoid arthritis, systemic lupus erythematosus, IgG4-related disease; (2) Drug-induced — amiodarone, methotrexate, nitrofurantoin, statins, biologics (TNF inhibitors, IL-6 inhibitors), chemotherapy (bleomycin, busulfan); (3) Chronic hypersensitivity pneumonitis (may show NSIP histologic pattern); (4) HIV/AIDS-associated; (5) Inherited pulmonary fibrosis (telomere disorders, surfactant gene mutations); (6) Familial NSIP.

Clinical presentation: more common in women (especially CTD-related); peak age 40–60 years (younger than IPF); insidious onset of progressive dyspnea on exertion (months to years), dry cough, fatigue; constitutional symptoms (low-grade fever, weight loss); systemic features of underlying CTD when present (skin tightness, sclerodactyly, calcinosis, Raynaud, telangiectasias in scleroderma; joint pain and morning stiffness in RA; dry eyes-mouth in Sjögren; muscle weakness and proximal myopathy with Gottron papules and heliotrope rash in dermatomyositis; mechanic's hands, fever, polyarthritis in antisynthetase syndrome); physical examination — bibasilar fine inspiratory crackles (less coarse than UIP, often called Velcro rales), digital clubbing in advanced disease (less common and prominent than IPF, occurring in 20 percent of NSIP), pulmonary hypertension features in advanced disease.

Symptoms

Insidious onset of progressive dyspnea on exertion (months to years)
Dry persistent cough
Fatigue and decreased exercise tolerance
Bibasilar fine inspiratory crackles (Velcro rales)
Digital clubbing in advanced disease (less common than IPF)
Constitutional symptoms — low-grade fever, weight loss
Systemic features of underlying connective tissue disease (depending on type)
Sclerodactyly, calcinosis, Raynaud phenomenon, telangiectasias (scleroderma)
Mechanic's hands, fever, arthritis, Raynaud (antisynthetase syndrome)
Heliotrope rash, Gottron papules, proximal myopathy (dermatomyositis)
Dry eyes and mouth, parotid swelling (Sjögren syndrome)
Joint deformity, morning stiffness (rheumatoid arthritis)
Pulmonary hypertension symptoms (right heart failure) in advanced disease

Risk Factors

Connective tissue disease (scleroderma >>> polymyositis-dermatomyositis > Sjögren > RA > MCTD)
Antisynthetase syndrome (anti-Jo-1 and other tRNA synthetase antibodies)
Drug exposure (amiodarone, methotrexate, nitrofurantoin, statins, biologics)
Chronic hypersensitivity pneumonitis history (occupational, environmental antigens)
Tobacco smoking (less strong association than IPF)
Female sex (especially CTD-related)
Middle age (40–60 years)
Family history of pulmonary fibrosis
HIV/AIDS
Telomere disorders or surfactant gene mutations (rare)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Progressive dyspnea on exertion in middle-aged person
  • Bilateral crackles on auscultation with respiratory symptoms
  • Connective tissue disease patient with new respiratory symptoms or imaging abnormalities
  • Antisynthetase syndrome features (mechanic's hands, fever, arthritis, Raynaud) with respiratory
  • Scleroderma patient for ILD screening (annual HRCT and PFT recommended)
  • Suspected drug-induced pulmonary toxicity (medication review)
  • Hypersensitivity pneumonitis evaluation (occupational history, environmental antigens)
  • Failed initial corticosteroid trial in interstitial lung disease (may need NSIP histologic confirmation)
  • Progressive fibrosing ILD requiring antifibrotic therapy consideration
  • End-stage NSIP for lung transplantation evaluation

Treatment Methods

01
Diagnostic workup: detailed history (onset, exposure to drugs, environmental antigens, occupational, family history), physical examination including assessment for connective tissue disease features, comprehensive serologic workup (CBC, CMP, ESR, CRP, ANA, ENA panel including anti-Scl-70, anti-centromere, anti-Jo-1 and other anti-synthetase antibodies — anti-PL-7, anti-PL-12, anti-EJ, anti-OJ, anti-KS, MDA-5, anti-PM-Scl, anti-Mi-2, RF, anti-CCP, anti-Ro/La, anti-Sm, anti-RNP, MPO/PR3-ANCA, complement C3/C4, IgG4 levels, hepatitis B/C, HIV)
02
Pulmonary function testing: spirometry (restrictive pattern with reduced TLC, FEV1, FVC, normal or elevated FEV1/FVC ratio), DLCO (reduced — important for severity and progression assessment), 6-minute walk test (oxygen desaturation, distance, important for prognosis and progression), arterial blood gas (resting and exercise hypoxemia)
03
Imaging: high-resolution CT (HRCT — characteristic NSIP pattern: bilateral, predominantly subpleural and basal ground-glass opacities, reticulation, traction bronchiectasis, often with subpleural sparing distinguishing from UIP; cellular NSIP — more ground-glass; fibrotic NSIP — more reticulation and traction bronchiectasis; absence of honeycombing helpful but small amount may be present in fibrotic NSIP); chest X-ray (less sensitive but shows bilateral interstitial pattern with basal predominance)
04
Multidisciplinary discussion (pulmonologist, radiologist, rheumatologist, pathologist when biopsy obtained) is gold standard for ILD diagnosis (ATS/ERS recommendation); when HRCT pattern is characteristic NSIP and clinical features support, biopsy may not be needed; surgical lung biopsy (video-assisted thoracoscopic surgery VATS) or transbronchial cryobiopsy if diagnosis uncertain
05
Treatment of cellular NSIP and inflammatory component: oral corticosteroids first-line — prednisolone 0.5–1 mg/kg/day initially (typically 1 mg/kg up to 60 mg max), maintained for 4–8 weeks, then gradually tapered over 6–12 months based on clinical response and side effect tolerance; assessment at 3 months — if improvement (≥10 percent FVC and DLCO improvement, symptom reduction, imaging stability), continue tapering; if no response or worsening, add steroid-sparing immunosuppressive
06
Steroid-sparing immunosuppressives: mycophenolate mofetil (CellCept) 500 mg twice daily titrated to 1500 mg twice daily — most commonly used adjunct, especially in CTD-NSIP and scleroderma-ILD; azathioprine 1.5–2 mg/kg/day (older alternative, hepatotoxicity, blood count monitoring required); cyclophosphamide IV pulse (500–1000 mg/m² every 2–4 weeks) or oral 1–2 mg/kg/day for severe rapidly progressive disease (often used with high-dose steroids in severe scleroderma-ILD); rituximab (anti-CD20) for refractory disease, particularly in antisynthetase syndrome and dermatomyositis-related NSIP, dosed as 1000 mg IV at 0 and 2 weeks then every 6 months
07
Antifibrotic therapy for fibrotic NSIP and progressive disease: nintedanib (Ofev, tyrosine kinase inhibitor) — 150 mg twice daily; FDA-approved 2014 for IPF, 2019 expanded to scleroderma-ILD (SENSCIS trial), 2020 expanded to all progressive fibrosing interstitial lung diseases including fibrotic NSIP (INBUILD trial — significant FVC decline reduction); diarrhea most common adverse event (up to 60 percent), hepatotoxicity, nausea; dose adjustment for tolerance; pirfenidone increasingly used in NSIP particularly in scleroderma-ILD off-label and in research trials (TRAIL1 trial in RA-ILD); newer antifibrotics in development (Bristol-Myers Squibb integrin alpha-v inhibitors, others)
08
Treatment of underlying connective tissue disease: scleroderma — disease-modifying treatment per rheumatology recommendations (mycophenolate, cyclophosphamide for ILD; tocilizumab — IL-6 antagonist showed promising effects on lung function in SENSCIS subgroup); polymyositis-dermatomyositis — corticosteroids plus immunosuppression (azathioprine, mycophenolate, IVIG, rituximab); antisynthetase syndrome — corticosteroids plus rituximab or other immunosuppression; RA — methotrexate caution given pulmonary toxicity, alternative DMARDs (leflunomide, hydroxychloroquine, biologics with attention to pulmonary safety); Sjögren — supportive care and immunosuppression as needed
09
Supportive care: pulmonary rehabilitation (improves exercise tolerance, dyspnea, quality of life), supplemental oxygen for resting or exertional hypoxemia (SpO2 <88 percent), pneumococcal and annual influenza vaccinations (avoid live vaccines on immunosuppression), management of comorbidities (GERD treatment as proton pump inhibitor and lifestyle, sleep apnea, pulmonary hypertension assessment with echocardiogram and right heart catheterization if indicated, depression and anxiety screening), smoking cessation
10
Lung transplantation: consideration for end-stage NSIP with progressive disease despite optimal medical therapy, severe lung function decline (FVC <50 percent predicted, DLCO <40 percent predicted, oxygen requirement, declining 6-minute walk test, recurrent hospitalization); referral to lung transplant center for evaluation when fitness assessment indicates candidacy; CTD patients require attention to extra-pulmonary involvement and multidisciplinary assessment
11
Long-term monitoring: clinical assessment every 3–6 months, PFTs every 3–6 months (FVC, DLCO trajectory most important), HRCT every 6–12 months or per clinical change, echocardiogram annually for pulmonary hypertension surveillance, labs for medication monitoring per regimen, multidisciplinary care (pulmonology, rheumatology, infectious disease for opportunistic infection prophylaxis, cardiology, palliative care for advanced disease)

Which Department to Visit?

You can visit our Göğüs Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Göğüs Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Nonspecific Interstitial Pneumonia (NSIP)

Göğüs Hastalıkları

Nonspecific interstitial pneumonia is a chronic interstitial lung disease characterized by uniform interstitial inflammation and/or fibrosis. It is frequently associated with connective tissue disease and generally responds to immunosuppression.

Asthma

Göğüs Hastalıkları

Asthma is characterized by wheezing, coughing and shortness of breath attacks; with proper treatment it can be kept under control.

COPD (Chronic Obstructive Pulmonary Disease)

Göğüs Hastalıkları

COPD is an irreversible lung disease characterized by shortness of breath and chronic cough; quitting smoking slows its progression.

Pneumonia

Göğüs Hastalıkları

Pneumonia presents with high fever, cough and shortness of breath; the vast majority recover with appropriate antibiotic treatment.

Tuberculosis (TB)

Göğüs Hastalıkları

Tuberculosis presents with weeks-to-months of cough, fever, and night sweats; early diagnosis and treatment lead to full recovery.

Pleural Effusion

Göğüs Hastalıkları

Pleural effusion is the accumulation of excess fluid in the pleural space, resulting from imbalances in fluid production and removal, and represents a manifestation of diverse cardiopulmonary, infectious, and malignant disorders.

Pneumothorax

Göğüs Hastalıkları

Pneumothorax is the presence of air in the pleural space resulting in partial or complete lung collapse, classified as spontaneous (primary/secondary), traumatic, or iatrogenic, with tension pneumothorax representing a life-threatening emergency.

Bronchitis (Acute and Chronic)

Göğüs Hastalıkları

Acute bronchitis is mostly viral and resolves spontaneously, while chronic bronchitis is a smoking-related component of COPD.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.